DIAGNOSIS AND RISK STRATIFICATION OF INFECTIONS AND CHRONIC DISEASES OF THE RESPIRATORY TRACT AND LUNGS BY MEANS OF PROVASOPRESSIN, PARTICULARLY COPEPTIN OR NEUROPHYSIN II

摘要

The diagnosing and risk level assessing device for lung infections involves detection of provasopressin (proAVP) or fragments and part-peptides of it such as copeptin or neurophysine II. The process is considered suitable for both symptomatic and asymptomatic patients, and particularly for emergency patients, and can identify patients at high risk or with an unfavorable prognosis of infections and chronic diseases of the airways.